The noradrenergic basis of Parkinson’s tremor: a systems-level fMRI approach - Noradrenergic basis of Parkinson tremor

Radboud University Nijmegen0 个研究点目标入组 60 人开始时间: 2017年1月17日最近更新: 2022年5月30日

适应症

试验速览

暂无简介。

•- idiopathic Parkinson’s disease according to UK Brain Bank criteria
•- tremor-dominant phenotype (defined as a resting tremor score of >= 2 UPDRS points for at least one arm)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 30
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 30

•-use of beta-blockers
•-neuropsychiatric co-morbidity
•-contraindications for MRI scanning (e.g. pacemaker, implanted metal parts, deep brain stimulation, claustrophobia)
•-Cardiac arrhythmias (in patient history or visible on ECG)
•-contraindications for beta blockers (e.g. bradycardia, peripheral circulation disturbances, asthma or obstructive lung disease, hypotension)
•-Use of medication that may interact with propranolol, e.g. other bèta-blockers, calcium antagonists, digoxine, cimetidine, hydralazine, fluvoxamine, rifampicine, barbiturates, amiodaron, flecainide, kinidine, propafenon, disopyramide, chlorpromazine, and clonidine
•-Use of medication that inhibits relevant CYP enzymes that are involved in metabolizing propranolol (CYP2D6, CYP1A2, and CYP2C19): fluoxetine, paroxetine, sertraline, duloxetine, terbinafine, cinacalcet, bupropion, and ciprofloxacine
•-Severe head tremor or dyskinesias
•-Cognitive impairment (MMSE < 26)

发起方